tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Guggenheim assumes Relay with Buy, names best idea

Guggenheim analyst Brad Canino assumed coverage of Relay Therapeutics (RLAY) with a Buy rating and price target of $15, up from $10. The analyst names Relay a “best idea.” The firm has high conviction in the company’s breast cancer potential and says it could undergo a nearer-term turnaround for the recently initiated development of RLY-2608 for vascular malformations. The company’s mutant-selective inhibitor could deliver substantial cross-trial increases in efficacy based, the analyst tells investors in a research note.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1